{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-237632","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.332753+00:00","generated_at":"2026-06-10T13:42:25.253972+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha discontinues TSHA-120 in GAN; extends cash runway to Q4 2025 for TSHA-102","bullets":["Taysha discontinues TSHA-120 for giant axonal neuropathy after FDA Type C feedback cited study design challenges for BLA.","Astellas Gene Therapies declined its option to license TSHA-120.","Cash runway extended into Q4 2025 by prioritizing TSHA-102 for Rett syndrome.","Ongoing REVEAL Phase 1/2 trial for TSHA-102 in adults; pediatric trial planned.","Taysha to pursue external strategic options for TSHA-120 to enable further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-237632","json":"https://secwatch.observer/filing/0001193125-23-237632.json","markdown":"https://secwatch.observer/filing/0001193125-23-237632.md","text":"https://secwatch.observer/filing/0001193125-23-237632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523237632/0001193125-23-237632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523237632/d511672d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T13:42:25.253972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}